Keytruda, Inlyta combo improves OS by 47%, PFS by 31% in first-line RCC

Merck & Co. reported detailed data from the Phase III KEYNOTE-426 trial of Keytruda pembrolizumab plus Inlyta axitinib as first-line treatment of renal cell carcinoma. New

Read the full 269 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE